Literature DB >> 16600444

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa.

Adrian W Zuercher1, Michael P Horn, Hong Wu, Zhijun Song, Cathrine J Bundgaard, Helle Krogh Johansen, Niels Høiby, Paul Marcus, Alois B Lang.   

Abstract

We tested intranasal application of anti-Pseudomonas conjugate vaccine in mice. Comparison of immunisation via the intra-muscular versus intranasal routes showed the induction of equivalent levels of specific serum IgG and IgG subclasses antibodies if cholera toxin was used as an adjuvant. In contrast, secretion of specific mucosal IgA antibodies in the upper respiratory tract was only observed after intranasal immunisation together with adjuvant. Systemic and mucosal immunity was also established via the intranasal route when CpG-containing oligonucleotides were used as adjuvant. The functionality of intranasally induced antibodies was proven in vitro by opsonophagocytosis and in vivo using the burn-wound sepsis and intra-tracheal lung infection models. These results demonstrate the feasibility of intranasal immunisation against P. aeruginosa with conjugate vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600444     DOI: 10.1016/j.vaccine.2006.03.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Glycosylation of pilin and nonpilin protein constructs by Pseudomonas aeruginosa 1244.

Authors:  Mohammed Qutyan; Matthew Henkel; Joseph Horzempa; Michael Quinn; Peter Castric
Journal:  J Bacteriol       Date:  2010-09-10       Impact factor: 3.490

2.  Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.

Authors:  Stefan Fernandez; Emily D Cisney; Shannan I Hall; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

3.  Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.

Authors:  Béatrice Heurtault; Philippe Gentine; Jean-Sébastien Thomann; Corinne Baehr; Benoît Frisch; Françoise Pons
Journal:  Pharm Res       Date:  2008-09-10       Impact factor: 4.200

4.  Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection.

Authors:  Joseph Horzempa; Thomas K Held; Alan S Cross; Dana Furst; Mohammed Qutyan; Alice N Neely; Peter Castric
Journal:  Clin Vaccine Immunol       Date:  2008-02-13

5.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

6.  Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.

Authors:  Stefan Fernandez; Emily D Cisney; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

7.  Adjuvant effects of Sijunzi decoction in chickens orally vaccinated with attenuated Newcastle-disease vaccine.

Authors:  Dianxin Zhang; Wanyu Shi; Yantao Zhao; Xiuhui Zhong
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-10-02

8.  Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Katie Harcher; Tanweer S Zaidi; Jason Gardner; Alice N Neely; Gerald B Pier; Joanna B Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

9.  Examining the role of nasopharyngeal-associated lymphoreticular tissue (NALT) in mouse responses to vaccines.

Authors:  Emily D Cisney; Stefan Fernandez; Shannan I Hall; Gale A Krietz; Robert G Ulrich
Journal:  J Vis Exp       Date:  2012-08-01       Impact factor: 1.355

10.  Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa.

Authors:  Irene Bianconi; Beatriz Alcalá-Franco; Maria Scarselli; Mattia Dalsass; Scilla Buccato; Annalisa Colaprico; Sara Marchi; Vega Masignani; Alessandra Bragonzi
Journal:  Front Immunol       Date:  2019-01-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.